ACRX (Mcap $54 M) 3x DRUGS IN PHASE 3 // RESULTS THIS MONTH =5 BAGGER EASILY !!!
This unknowm lof float monster will fly into double digits once the investors discover this Goldmine . FIRST PHASE 3 RESULTS THIS MONTH THIS WILL PUSH THIS LOW FLOAT ROCKET TO $5-6 EASILY .
ACRX has 3x Products in Phase 3 two of them have BLOCKBUSTER POTENTIAL . Institutions & Management bought over 560K shrs for $3.40 which is much higher from current huge bargain level of $2.89 .
AcelRx Pharma (ACRX)
Mcap: $54 M
Cash: $24 M
Shares Out : 19.5 M SHRS (LOW FLOAT :ONLY 6.4 M SHRS)
Dosing of the last patient in the Phase 3 open label, active comparator study comparing efficacy and safety of the Sufentanil NanoTab System to the commonly used IV PCA with morphine is complete, and top line data are expected in November, 2012. Top line results from the two placebo-controlled Phase 3 clinical studies, one treating post-operative pain in patients following abdominal surgery and the other treating post-operative pain in patients following hip or knee replacement, are both expected during the first quarter of 2013.